☆ 4.6 Article

Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

DIABETES & METABOLISM (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor

Johanna Helmstaedter et al.

Summary: Cardiovascular outcome trials have shown cardiovascular benefits for type 2 diabetes mellitus patients treated with long-acting GLP-1 receptor agonists. However, the effects of GLP-1 and receptor agonists on the cardiovascular system are not fully understood. Further research is needed to explore the potential cardiovascular protection beyond glycaemic control offered by GLP-1 receptor agonists.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

Elisabetta Patorno et al.

Summary: In older adults, individuals initiating SGLT2i had similar MACE risk, decreased risk of HHF, and increased risk of DKA, LLA, and genital infections compared to those initiating GLP-1RA.

DIABETES CARE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study

Sanjoy K. Paul et al.

Summary: This study evaluated the risk of amputations in patients with type 2 diabetes treated with different anti-diabetic drugs, finding that SGLT-2i and incretins did not increase the risk compared to other ADDs. Pre-existing peripheral artery disease (PAD) was identified as the major driver of amputation risk.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Surgery

Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis

Roman N. Rodionov et al.

Summary: This study examined the association between HHF and LEA in patients with type 2 diabetes and PAD initiating SGLT2 inhibitors, before and after the EMA warning in 2017. The study found that PAD patients generally have higher amputation risks and that the differences in outcomes among study groups decreased after the EMA warning, indicating that regulatory surveillance measures were effective.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2021)

添加到收藏夹

Review Medicine, General & Internal

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Suetonia C. Palmer et al.

Summary: This network meta-analysis evaluated the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk levels. The study found that both classes of drugs lowered mortality and improved cardiovascular outcomes, with notable differences in effects between the two agents. Additional benefits and adverse effects varied across different risk groups.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis

Mei Qiu et al.

Summary: This study conducted a network meta-analysis on large sample studies to evaluate the relative risk of different SGLT2is and NonSGLT2i antihyperglycemic drugs in leading to amputation. The results showed that SGLT2is, especially canagliflozin, significantly increased the risk of amputation compared to NonSGLT2is. There was no significant difference in amputation risk between SGLT2is and placebo.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Moa Lugner et al.

Summary: This observational study indicated that treatment with GLP-1RA and SGLT-2i result in very similar cardiorenal outcomes. In the short term, treatment with GLP-1RA seem to be associated with lower risks of stroke and peripheral artery disease, whereas SGLT-2i seem to be nominally associated with lower risk of heart failure and total mortality.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan

Hsien-Yen Chang et al.

Summary: After comparing the risks of clinical outcomes, mortality, and healthcare costs among new users of different classes of anti-diabetic medications, it was found that new users of SGLT-2 inhibitors had lower mortality rates compared to users of DPP-4 inhibitors, and lower healthcare costs compared to users of GLP-1 agonists.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors

Donna Shu-Han Lin et al.

Summary: The study revealed that in patients with type 2 diabetes, the use of GLP1RAs was associated with significantly lower risks of major adverse limb events compared to DPP4is. The reduction in risk was primarily due to decreased rates of amputations.

DIABETOLOGIA (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study

Sanjoy K. Paul et al.

Summary: This study aimed to evaluate the temporal pattern of amputations in T2DM patients, the risk of amputations by different types of anti-diabetic drugs, and the interplay of PAD with therapy and amputation risk. The results showed that the risk of amputation was not higher in patients treated with SGLT-2i and incretins compared to other ADDs, and pre-existing PAD was the greatest driver of amputation risk.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Andre J. Scheen

NATURE REVIEWS ENDOCRINOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Glucagon-like peptide-1 receptor action in the vasculature

Malak Almutairi et al.

PEPTIDES (2019)

添加到收藏夹

Editorial Material Endocrinology & Metabolism

Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new 'French paradox'

A. J. Scheen et al.

DIABETES & METABOLISM (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease Results From the EXSCEL Trial

Anish Badjatiya et al.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden

Henrik Svanstrom et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Andre J. Scheen

DIABETES RESEARCH AND CLINICAL PRACTICE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

The safety of gliptins : updated data in 2018

Andre Jacques Scheen

EXPERT OPINION ON DRUG SAFETY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Ketan Dhatariya et al.

DIABETES CARE (2018)

添加到收藏夹

Article Medicine, General & Internal

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

Hsien-Yen Chang et al.

JAMA INTERNAL MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Peter Ueda et al.

BMJ-BRITISH MEDICAL JOURNAL (2018)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Endocrinology & Metabolism

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists

Andre J. Scheen

DIABETES RESEARCH AND CLINICAL PRACTICE (2017)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.